LOX-1与肿瘤的相关性研究进展

Research Progress on the Correlation between LOX-1 and Tumors

代谢紊乱和肿瘤发生、发展密切相关,靶向癌症代谢途径成为抗肿瘤治疗的新靶点。凝集素样氧化低密度脂蛋白(LOX-1)是氧化低密度脂蛋白(ox-LDL)的受体,两者通过结合发挥促进动脉粥样硬化形成的作用。LOX-1在多种实体肿瘤中高表达,证实其与肿瘤的发生、发展存在密切关系。在本综述中主要阐明了在前列腺癌、结直肠癌、胰腺癌、肺癌、胃癌和乳腺癌这些不同的实体瘤中,LOX-1通过促进新生血管形成和促上皮–间充质转化等机制实现抗肿瘤作用。在肿瘤的相关性研究进展中,LOX-1有望成为抗肿瘤治疗的新靶点。

Metabolic disorders are closely related to tumorigenesis and development, and targeting cancer metabolic pathway has become a new target for anti-tumor therapy. Lectin-like oxidized low- den-sity lipoprotein (LOX-1) is a receptor for oxidizing low-density lipoprotein (ox-LDL), and the two play a role in promoting atherosclerotic formation by binding. LOX-1 is highly expressed in a variety of solid tumors, which confirms that it is closely related to the occurrence and development of tumors. In this review, LOX-1 achieves anti-tumor effects by promoting neovascularization and promoting epithelial-mesenchymal conversion in different solid tumors of prostate, colorectal, pancreatic, lung, gastric and breast cancers. In the progress of tumor correlation research, LOX-1 is expected to be-come a new target for anti-tumor therapy.